keyword
MENU ▼
Read by QxMD icon Read
search

Broadly neutralizing antibody

keyword
https://www.readbyqxmd.com/read/27919754/neutralization-takes-precedence-over-igg-or-iga-isotype-related-functions-in-mucosal-hiv-1-antibody-mediated-protection
#1
Rena D Astronomo, Sampa Santra, Lamar Ballweber-Fleming, Katharine G Westerberg, Linh Mach, Tiffany Hensley-McBain, Laura Sutherland, Benjamin Mildenberg, Georgeanna Morton, Nicole L Yates, Gregory J Mize, Justin Pollara, Florian Hladik, Christina Ochsenbauer, Thomas N Denny, Ranjit Warrier, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayapan, Jaranit Kaewkungwal, Guido Ferrari, George M Shaw, Shi-Mao Xia, Hua-Xin Liao, David C Montefiori, Georgia D Tomaras, Barton F Haynes, M Juliana McElrath
HIV-1 infection occurs primarily through mucosal transmission. Application of biologically relevant mucosal models can advance understanding of the functional properties of antibodies that mediate HIV protection, thereby guiding antibody-based vaccine development. Here, we employed a human ex vivo vaginal HIV-1 infection model and a rhesus macaque in vivo intrarectal SHIV challenge model to probe the protective capacity of monoclonal broadly-neutralizing (bnAb) and non-neutralizing Abs (nnAbs) that were functionally modified by isotype switching...
November 21, 2016: EBioMedicine
https://www.readbyqxmd.com/read/27914743/sequential-immunization-with-consensus-influenza-hemagglutinins-raises-cross-reactive-neutralizing-antibodies-against-various-heterologous-ha-strains
#2
Hui Zhou, Yang Huang, Songhua Yuan, Yuanyuan Li, Shuyan Wu, Jianqing Xu, Rui Huang
Seasonal and emerging epidemics caused by influenza virus remain as a public health concern and an economic burden. The weak immunogenicity of conserved epitopes on hemagglutinin that induces broad protective immune responses is the main obstacle to the development of universal vaccines. In the present report, we designed the cross-subtypic sequential vaccination strategy and evaluated its neutralizing antibody (nAb) activity by pseudovirus-based neutralization assays. The results clearly indicated that compared with traditional vaccines strategy, the cross-subtypic sequential immunization could significantly induce a broad serum cross-reactive nAb response in mice as well as against homologous strains, and provide protection from heterologous virus PR8 (H1N1) challenge...
November 30, 2016: Vaccine
https://www.readbyqxmd.com/read/27914742/influenza-virus-specific-antibody-dependent-cellular-cytoxicity-induced-by-vaccination-or-natural-infection
#3
Rory D de Vries, Nella J Nieuwkoop, Mark Pronk, Erwin de Bruin, Geert Leroux-Roels, Elisabeth G W Huijskens, Rob S van Binnendijk, Florian Krammer, Marion P G Koopmans, Guus F Rimmelzwaan
Influenza viruses are responsible for substantial morbidity and mortality during seasonal epidemics. Vaccination is the most effective method to prevent infection, however due to antigenic drift of the viral surface protein hemagglutinin (HA), annual influenza virus vaccination is required. In addition to seasonal viruses, certain (avian) influenza A viruses of other subtypes, like H5N1 or H7N9, cause sporadic zoonotic infections. Therefore, the availability of game-changing novel vaccines that induce "universal" immune responses to a wide variety of influenza A virus subtypes is highly desirable...
November 30, 2016: Vaccine
https://www.readbyqxmd.com/read/27910950/human-antibody-3e1-targets-the-ha-stem-region-of-h1n1-and-h5n6-influenza-a-viruses
#4
Wenshuai Wang, Xiaoyu Sun, Yanbing Li, Jinpeng Su, Zhiyang Ling, Tianlong Zhang, Fang Wang, Hong Zhang, Hualan Chen, Jianping Ding, Bing Sun
As influenza A viruses remain a major threat to human health worldwide, the discovery of broadly neutralizing monoclonal antibodies that recognize conserved epitopes would facilitate the development of antibody-based therapeutic strategies. Here we report that a VH4-4-encoded human mAb named 3E1 could neutralize H1 and H5 subtype viruses in vitro and protect mice against the H1N1 and H5N6 viruses by inhibiting the low pH-induced conformational rearrangement of haemagglutinin (HA), hence blocking membrane fusion...
December 2, 2016: Nature Communications
https://www.readbyqxmd.com/read/27908641/free-energy-perturbation-calculation-of-relative-binding-free-energy-between-broadly-neutralizing-antibodies-and-the-gp120-glycoprotein-of-hiv-1
#5
Anthony J Clark, Tatyana Gindin, Baoshan Zhang, Lingle Wang, Robert Abel, Colleen S Murret, Fang Xu, Amy Bao, Nina J Lu, Tongqing Zhou, Peter D Kwong, Lawrence Shapiro, Barry Honig, Richard A Friesner
Direct calculation of relative binding affinities between antibodies and antigens is a long-sought goal. However, despite substantial efforts, no generally applicable computational method has been described. Here we describe a systematic free energy perturbation (FEP) protocol and calculate the binding affinities between the gp120 envelope glycoprotein of HIV-1 and three broadly neutralizing antibodies (bNAbs) of the VRC01 class. The protocol has been adapted from successful studies of small molecules to address the challenges associated with modeling protein-protein interactions...
November 28, 2016: Journal of Molecular Biology
https://www.readbyqxmd.com/read/27905530/structural-basis-for-broad-neutralization-of-hiv-1-through-the-molecular-recognition-of-10e8-helical-epitope-at-the-membrane-interface
#6
Edurne Rujas, Jose M M Caaveiro, Angélica Partida-Hanon, Naveed Gulzar, Koldo Morante, Beatriz Apellániz, Miguel García-Porras, Marta Bruix, Kouhei Tsumoto, Jamie K Scott, M Ángeles Jiménez, José L Nieva
The mechanism by which the HIV-1 MPER epitope is recognized by the potent neutralizing antibody 10E8 at membrane interfaces remains poorly understood. To solve this problem, we have optimized a 10E8 peptide epitope and analyzed the structure and binding activities of the antibody in membrane and membrane-like environments. The X-ray crystal structure of the Fab-peptide complex in detergents revealed for the first time that the epitope of 10E8 comprises a continuous helix spanning the gp41 MPER/transmembrane domain junction (MPER-N-TMD; Env residues 671-687)...
December 1, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27894306/first-phase-i-human-clinical-trial-of-a-killed-whole-hiv-1-vaccine-demonstration-of-its-safety-and-enhancement-of-anti-hiv-antibody-responses
#7
Eunsil Choi, Chad J Michalski, Seung Ho Choo, Gyoung Nyoun Kim, Elizabeth Banasikowska, Sangkyun Lee, Kunyu Wu, Hwa-Yong An, Anthony Mills, Stefan Schneider, U Fritz Bredeek, Daniel R Coulston, Shilei Ding, Andrés Finzi, Meijuan Tian, Katja Klein, Eric J Arts, Jamie F S Mann, Yong Gao, C Yong Kang
BACKGROUND: Vaccination with inactivated (killed) whole-virus particles has been used to prevent a wide range of viral diseases. However, for an HIV vaccine this approach has been largely negated due to inherent safety concerns, despite the ability of killed whole-virus vaccines to generate a strong, predominantly antibody-mediated immune response in vivo. HIV-1 Clade B NL4-3 was genetically modified by deleting the nef and vpu genes and substituting the coding sequence for the Env signal peptide with that of honeybee melittin signal peptide to produce a less virulent and more replication efficient virus...
November 28, 2016: Retrovirology
https://www.readbyqxmd.com/read/27891132/impact-of-chronic-hiv-siv-infection-on-t-follicular-helper-cell-subsets-and-germinal-center-homeostasis
#8
REVIEW
Stéphanie Graff-Dubois, Angeline Rouers, Arnaud Moris
The discovery of broad and potent HIV-1 neutralizing antibodies (bNAbs) has renewed optimism for developing an effective vaccine against HIV-1. The generation of most bNAbs requires multiple rounds of B cell receptor affinity maturation, suggesting a crucial role of follicular helper T (Tfh) cells in their production. However, less than 1% of HIV-infected patients develop bNAbs that arise late in the course of infection, indicating probable Tfh and B cell dysfunctions in this context. Since the last few years, many studies have characterized Tfh cells from lymph nodes and spleen of HIV-infected individuals and SIV-infected macaques...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27890774/inhibition-of-local-effects-induced-by-bothrops-erythromelas-snake-venom-assessment-of-the-effectiveness-of-brazilian-polyvalent-bothropic-antivenom-and-aqueous-leaf-extract-of-jatropha-gossypiifolia
#9
Juliana Félix-Silva, Jacyra A S Gomes, Jacinthia B Xavier-Santos, Júlia G R Passos, Arnóbio A Silva-Junior, Denise V Tambourgi, Matheus F Fernandes-Pedrosa
Bothrops erythromelas is a snake of medical importance responsible for most of the venomous incidents in Northeastern Brazil. However, this species is not included in the pool of venoms that are used in the Brazilian polyvalent bothropic antivenom (BAv) production. Furthermore, it is well known that antivenom therapy has limited efficacy against venom-induced local effects, making the search for complementary alternatives to treat snakebites an important task. Jatropha gossypiifolia is a medicinal plant widely indicated in folk medicine as an antidote for snakebites, whose effectiveness against Bothrops jararaca venom (BjV) has been previously demonstrated in mice...
November 25, 2016: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/27889616/developments-in-l2-based-human-papillomavirus-hpv-vaccines
#10
REVIEW
Christina Schellenbacher, Richard B S Roden, Reinhard Kirnbauer
Infections with sexually transmitted high-risk Human Papillomavirus (hrHPV), of which there are at least 15 genotypes, are responsible for a tremendous disease burden by causing cervical, and subsets of other ano-genital and oro-pharyngeal carcinomas, together representing 5% of all cancer cases worldwide. HPV subunit vaccines consisting of virus-like particles (VLP) self-assembled from major capsid protein L1 plus adjuvant have been licensed. Prophylactic vaccinations with the 2-valent (HPV16/18), 4-valent (HPV6/11/16/18), or 9-valent (HPV6/11/16/18/31/33/45/52/58) vaccine induce high-titer neutralizing antibodies restricted to the vaccine types that cause up to 90% of cervical carcinomas, a subset of other ano-genital and oro-pharyngeal cancers and 90% of benign ano-genital warts (condylomata)...
November 23, 2016: Virus Research
https://www.readbyqxmd.com/read/27889424/hiv-vaccines-one-step-closer
#11
Michael Sze Yuan Low, David Tarlinton
Currently there is no effective vaccine against human immunodeficiency virus (HIV). Four recently published studies in Cell and Immunity now show that using planned sequential boosting with antigens to guide the humoral response towards broadly neutralizing antibodies could provide a solution to achieving vaccination against HIV-1.
November 23, 2016: Trends in Molecular Medicine
https://www.readbyqxmd.com/read/27881658/porcine-reproductive-and-respiratory-syndrome-virus-antagonizes-jak-stat3-signaling-via-nsp5-by-inducing-stat3-degradation
#12
Liping Yang, Rong Wang, Zexu Ma, Yueqiang Xiao, Yuchen Nan, Yu Wang, Shaoli Lin, Yan-Jin Zhang
: Signal transducer and activator of transcription 3 (STAT3) is a pleiotropic signaling mediator of many cytokines including interleukin-6 (IL-6) and IL-10. STAT3 is known to play critical roles in cell growth, proliferation, differentiation, immunity and inflammatory responses. The objective of this study was to determine the effect of porcine reproductive and respiratory syndrome virus (PRRSV) infection on the STAT3 signaling since PRRSV induces a weak protective immune response in host animals...
November 23, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27879316/structure-based-design-of-cyclically-permuted-hiv-1-gp120-trimers-that-elicit-neutralizing-antibodies
#13
Sannula Kesavardhana, Raksha Das, Michael Citron, Rohini Datta, Linda Ecto, Nonavinakere Seetharam Srilatha, Daniel DiStefano, Ryan Swoyer, Joseph G Joyce, Somnath Dutta, Celia C LaBranche, David C Montefiori, Jessica A Flynn, Raghavan Varadarajan
A major goal for HIV-1 vaccine development is an ability to elicit strong and durable broadly neutralizing antibody (bNAb) responses. The trimeric envelope glycoprotein (Env) spikes on HIV-1 are known to contain multiple epitopes that are susceptible to bNAbs isolated from infected individuals. Nonetheless, all trimeric and monomeric Env immunogens designed to date have failed to elicit such antibodies. We report the structure guided design of HIV-1 cyclically permuted gp120 that forms homogeneous, stable trimers and displays enhanced binding to multiple bNAbs, including VRC01, VRC03, VRC-PG04, PGT128 and the quaternary epitope-specific bNAbs PGT145 and PGDM1400...
November 22, 2016: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27871328/membrane-bound-modified-form-of-clade-b-env-jrcsf-is-suitable-for-immunogen-design-as-it-is-efficiently-cleaved-and-displays-all-the-broadly-neutralizing-epitopes-including-v2-and-c2-domain-dependent-conformational-epitopes
#14
Supratik Das, Saikat Boliar, Nivedita Mitra, Sweety Samal, Manish Bansal, Wayne C Koff, Bimal K Chakrabarti
BACKGROUND: Antigenicity of HIV-1 envelope proteins (Envs) of both lab-adapted and primary isolates expressed on the cell surface rarely match with in vitro neutralization of viruses, pseudo-typed with corresponding Envs. Often, both neutralizing and non-neutralizing antibodies bind to Envs expressed on the cell membrane. This could be due to the lack of efficient cleavage of Env expressed on the cell surface. Naturally occurring, efficiently cleaved Envs with appropriate antigenic properties are relatively rare...
November 21, 2016: Retrovirology
https://www.readbyqxmd.com/read/27869733/antiviral-therapy-by-hiv-1-broadly-neutralizing-and-inhibitory-antibodies
#15
REVIEW
Zhiqing Zhang, Shaowei Li, Ying Gu, Ningshao Xia
Human immunodeficiency virus type 1 (HIV-1) infection causes acquired immune deficiency syndrome (AIDS), a global epidemic for more than three decades. HIV-1 replication is primarily controlled through antiretroviral therapy (ART) but this treatment does not cure HIV-1 infection. Furthermore, there is increasing viral resistance to ART, and side effects associated with long-term therapy. Consequently, there is a need of alternative candidates for HIV-1 prevention and therapy. Recent advances have discovered multiple broadly neutralizing antibodies against HIV-1...
November 18, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27861998/a-two-step-screening-approach-for-the-identification-of-blood-donors-with-highly-and-broadly-neutralizing-capacities-against-human-cytomegalovirus
#16
Jessica J Falk, Martina Winkelmann, Hubert Schrezenmeier, Dagmar Stöhr, Christian Sinzger, Ramin Lotfi
BACKGROUND: Hyperimmunoglobulins are frequently applied for prophylaxis and treatment of human cytomegalovirus (HCMV) infections but were only marginally effective in meta-analyses of clinical studies. This might be partially due to selection of donors rather for total anti-HCMV titers than for neutralizing capacities. To improve efficacy against HCMV infection, we aimed at developing a high-throughput screening method for identification of blood donors with highly and broadly neutralizing capacities...
November 10, 2016: Transfusion
https://www.readbyqxmd.com/read/27853288/enhancing-virion-tethering-by-bst2-sensitizes-productively-and-latently-hiv-infected-t-cells-to-adcc-mediated-by-broadly-neutralizing-antibodies
#17
Tram N Q Pham, Sabelo Lukhele, Frédéric Dallaire, Gabrielle Perron, Éric A Cohen
Binding of anti-HIV antibodies (Abs) to envelope (Env) glycoproteins on infected cells can mark them for elimination via antibody-dependent cell-mediated cytotoxicity (ADCC). BST2, a type I interferon (IFN)-stimulated restriction factor that anchors nascent Env-containing virions at the surface of infected cells has been shown to enhance ADCC functions. In a comprehensive analysis of ADCC potency by neutralizing anti-HIV Abs (NAbs), we show in this study that NAbs are capable of mediating ADCC against HIV-infected T cells with 3BNC117, PGT126 and PG9 being most efficient...
November 17, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27851923/hiv-broadly-neutralizing-antibodies-taking-good-care-of-the-98
#18
Devin Sok, Dennis R Burton
In this issue of Immunity, Huang et al. (2016) describe an exceptionally broad and potent neutralizing antibody to HIV. This antibody, N6, is capable of neutralizing up to 98% of global isolates with a potent median IC50 of 0.04 μg/mL, making it the current "best-in-class" for bNAbs targeting the CD4 binding site.
November 15, 2016: Immunity
https://www.readbyqxmd.com/read/27851912/identification-of-a-cd4-binding-site-antibody-to-hiv-that-evolved-near-pan-neutralization-breadth
#19
Jinghe Huang, Byong H Kang, Elise Ishida, Tongqing Zhou, Trevor Griesman, Zizhang Sheng, Fan Wu, Nicole A Doria-Rose, Baoshan Zhang, Krisha McKee, Sijy O'Dell, Gwo-Yu Chuang, Aliaksandr Druz, Ivelin S Georgiev, Chaim A Schramm, Anqi Zheng, M Gordon Joyce, Mangaiarkarasi Asokan, Amy Ransier, Sam Darko, Stephen A Migueles, Robert T Bailer, Mark K Louder, S Munir Alam, Robert Parks, Garnett Kelsoe, Tarra Von Holle, Barton F Haynes, Daniel C Douek, Vanessa Hirsch, Michael S Seaman, Lawrence Shapiro, John R Mascola, Peter D Kwong, Mark Connors
Detailed studies of the broadly neutralizing antibodies (bNAbs) that underlie the best available examples of the humoral immune response to HIV are providing important information for the development of therapies and prophylaxis for HIV-1 infection. Here, we report a CD4-binding site (CD4bs) antibody, named N6, that potently neutralized 98% of HIV-1 isolates, including 16 of 20 that were resistant to other members of its class. N6 evolved a mode of recognition such that its binding was not impacted by the loss of individual contacts across the immunoglobulin heavy chain...
November 15, 2016: Immunity
https://www.readbyqxmd.com/read/27846415/chinks-in-the-armor-of-the-hiv-1-envelope-glycan-shield-implications-for-immune-escape-from-anti-glycan-broadly-neutralizing-antibodies
#20
Thandeka Moyo, Roux-Cil Ferreira, Reyaaz Davids, Zarinah Sonday, Penny L Moore, Simon A Travers, Natasha T Wood, Jeffrey R Dorfman
Glycans on HIV-1 Envelope serve multiple functions including blocking epitopes from antibodies. We show that removal of glycan 301, a major target of anti-V3/glycan antibodies, has substantially different effects in two viruses. While glycan 301 on Du156.12 blocks epitopes commonly recognized by sera from chronically HIV-1-infected individuals, it does not do so on CAP45.G3, suggesting that removing the 301 glycan has a smaller effect on the integrity of the glycan shield in CAP45.G3. Changes in sensitivity to broadly neutralizing monoclonal antibodies suggest that the interaction between glycan 301 and the CD4 binding site differ substantially between these 2 viruses...
November 12, 2016: Virology
keyword
keyword
34044
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"